GoodRx backer sells 1.57M shares at ~$3.50
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
GoodRx Holdings, Inc. (GDRX) was the subject of a Form 4 in which investment funds affiliated with Francisco Partners reported open‑market sales of an aggregate 1,567,044 shares of Class A Common Stock on August 24–26, 2026, at weighted average prices ranging from about $3.44 to $3.51 per share. The shares were held indirectly through Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P.; associated general partner and management entities may be deemed to share voting and dispositive power but disclaim beneficial ownership. The filing indicates the transactions were not made pursuant to a Rule 10b5-1 trading plan.
Insights
Analyzing...
Insider Trade Summary
Net Seller: 1,567,044 shares
Net Sell
8 txns
Insider
FRANCISCO PARTNERS IV, L.P., FRANCISCO PARTNERS IV-A, L.P., Francisco Partners GP IV, L.P., Francisco Partners GP IV Management Ltd, Francisco Partners Management, LP
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold
1,567,044 shs ($5.48M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock F5, F3 | 213,401 | $3.5125 | $750K |
| Sale | Class A Common Stock F5, F3 | 210,378 | $3.5125 | $739K |
| Sale | Class A Common Stock F3 | 439,310 | $3.50 | $1.54M |
| Sale | Class A Common Stock F3 | 433,088 | $3.50 | $1.52M |
| Sale | Class A Common Stock F4, F3 | 64,090 | $3.4449 | $221K |
| Sale | Class A Common Stock F4, F3 | 63,183 | $3.4449 | $218K |
| Sale | Class A Common Stock F1, F2, F3 | 72,309 | $3.462 | $250K |
| Sale | Class A Common Stock F1, F2, F3 | 71,285 | $3.462 | $247K |
Holdings After Transaction:
Class A Common Stock — 0 shares (Indirect, By Francisco Partners IV, L.P.);
Class A Common Stock — 0 shares (Indirect, By Francisco Partners IV-A, L.P.)
Footnotes (5)
- F1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions on 8/24/2026 at prices ranging from $3.425 to $3.5 per share, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The reported amount has been adjusted by 721 shares to reflect the sale of such shares by Francisco Partners IV-A, L.P. on August 20, 2026, which were inadvertently reported on a Form 4 filed by the reporting persons on August 21, 2026, as being sold by Francisco Partners IV, L.P.
- F3. Francisco Partners GP IV, L.P. is the general partner of each of Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. Francisco Partners GP IV Management Limited is the general partner of Francisco Partners GP IV, L.P. Francisco Partners Management, L.P. serves as the investment manager for each of Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. Voting and disposition decisions at Francisco Partners Management, L.P. with respect to the shares of Class B common stock held by Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. are made by an investment committee. Each of Francisco Partners Management, L.P., Francisco Partners GP IV Management Limited, and Francisco Partners GP IV, L.P. may be deemed to share voting and dispositive power over the shares of Class B common stock held, but disclaims beneficial ownership.
- F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions on 8/25/2026 at prices ranging from $3.415 to $3.48 per share, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions on 8/26/2026 at prices ranging from $3.44 to $3.545 per share, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Total shares sold: 1,567,044 shares
Sale on 2026-08-24 by Francisco Partners IV, L.P.: 72,309 shares at $3.4620 per share
Sale on 2026-08-24 by Francisco Partners IV-A, L.P.: 71,285 shares at $3.4620 per share
+5 more
8 metrics
Total shares sold
1,567,044 shares
Aggregate non-derivative sales of GoodRx Class A Common Stock reported in this Form 4
Sale on 2026-08-24 by Francisco Partners IV, L.P.
72,309 shares at $3.4620 per share
Open-market sale of GoodRx Class A Common Stock on August 24, 2026
Sale on 2026-08-24 by Francisco Partners IV-A, L.P.
71,285 shares at $3.4620 per share
Open-market sale of GoodRx Class A Common Stock on August 24, 2026
Sale on 2026-08-25 by Francisco Partners IV, L.P.
64,090 shares at $3.4449 per share
Open-market sale of GoodRx Class A Common Stock on August 25, 2026
Sale on 2026-08-25 by Francisco Partners IV-A, L.P.
63,183 shares at $3.4449 per share
Open-market sale of GoodRx Class A Common Stock on August 25, 2026
Sale on 2026-08-26 by Francisco Partners IV, L.P. (first block)
213,401 shares at $3.5125 per share
Weighted average price; trades on August 26, 2026 within $3.44–$3.545 range
Sale on 2026-08-26 by Francisco Partners IV-A, L.P. (first block)
210,378 shares at $3.5125 per share
Weighted average price; trades on August 26, 2026 within $3.44–$3.545 range
Additional sales on 2026-08-26
439,310 and 433,088 shares at $3.5000 per share
Open-market sales of GoodRx Class A Common Stock by both funds on August 26, 2026
Key Terms
weighted average price, Class A Common Stock, ten percent owner, dispositive power, +1 more
5 terms
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Class A Common Stock financial
"security_title": "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
ten percent owner regulatory
"each is_ten_percent_owner": 1"
dispositive power financial
"may be deemed to share voting and dispositive power over the shares"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
beneficial ownership regulatory
"may be deemed to share voting and dispositive power ... but disclaims beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
On what dates did the GoodRx (GDRX) insider sales occur and at what prices?
The reported sales occurred on August 24, 25, and 26, 2026, with weighted average prices per share of $3.4620 on August 24, $3.4449 on August 25, and $3.50–$3.5125 on August 26. Footnotes state the shares traded within price ranges around these averages.
Were the GoodRx (GDRX) insider sales made under a Rule 10b5-1 trading plan?
No. The Form 4’s Rule 10b5‑1 checkbox indicates false, meaning the reporting persons did not affirm that these GoodRx share sales were executed pursuant to a Rule 10b5‑1 or similar pre‑arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
